Endoprosthesis for the treatment of type A aortic dissection

Original title: Application of Open Triple-Branch Aortic Arch Stent Graff for Acute Stanford Type A Aortic Dissection Reference: Fei Hua, et; al. Vascular Endovascular Surgery 47;2:109-14

Type A aortic dissection is a disease of high morbidity and mortality, especially in the early hours . Surgery is the treatment of choice but still have a significant complication rate .

We analyzed 34 patients with type A aortic dissection treated with branched stent for neck vessels ( Aortec Medical Technology Co Ltd , Beijing , China ) and were compared with 16 patients who underwent conventional surgery . No significant differences in baseline characteristics of both groups.

The procedure was performed under general anesthesia with median stereotomy, cardiopulmonary bypass , blood cardioplegia and deep hypothermia before implantation of the stent and its branches. The group that received stents had lower cardiopulmonary bypass time ( 186 ± 38 min . Versus 204 ± 47 min .), lower myocardial ischemic  time ( 101 ± 27 min . Versus 119 ± 30 min .) , shorter selective brain perfusion time ( 39 ± 11 min . Versus 46 ± 11 min . ) , as well as mechanical ventilation assistance  (19.9 ± 3.4 hours versus 20.4 ± 3.7 hours. ) And stay in intensive care (82.1 ± 11.2 hours. Versus  89.2 ± 13.1 hours.) During hospitalization 2 patients died, one required dialysis , 2 evolved with arm mobility impairments and one  presented consciousness disorders. At 9.6 months (2-24 months) follow-up , no patient died and only one had right arm motility difficulty  and required rehabilitation. Control tomography was performed in all patients witnessing a correct stent implantation with the preserved flow in the legs without significant leaks .

Conclusion:

This stent would be useful for those patients who require surgical reconstruction of the thoracic aorta , thus reducing the time of cardiopulmonary bypass from traditional surgery and potential complications thereof . 

Comment:

While this is a small population, indicates that it was possible to satisfactory solve, with this strategy favorably resolve such a complex disease , reducing surgical time and intensive areas and a good performance in the medium term. 

Courtesy by Dr Carlos Fava
Interventional Cardiologist
Favaloro Foundation
Buenos Aires – Argentina

Dr. Carlos Fava para SOLACI.ORG

More articles by this author

Transcatheter Pulmonary Valve Implantation with a Self-Expanding Valve: Outcomes at 3 Years

Pulmonary regurgitation (PR) is a common condition in patients who have undergone surgical repair of Tetralogy of Fallot or other pathologies involving the right...

RACE Trial: Effect of Balloon Pulmonary Angioplasty and Riociguat on Right Ventricular Afterload and Function in Chronic Thromboembolic Pulmonary Hypertension

Even though pulmonary endarterectomy is the treatment of choice for chronic thromboembolic pulmonary hypertension (CTEPH), up to 40% of patients are not candidates because...

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Pretreatment with DAPT in Acute Coronary Syndrome: An Ongoing Debate?

In acute coronary syndrome (ACS) dual antiplatelet therapy (DAPT) has become a fundamental pillar after percutaneous coronary intervention (PCI), preventing stent thrombosis and acute...

Measuring Post-TAVI Gradients and Their Implications: Are Invasive and Echocardiographic Assessments Comparable?

Transcatheter aortic valve implantation (TAVI) is considered the treatment of choice for a significant proportion of patients with symptomatic aortic stenosis. Outcomes have improved...

Another Blow for Intra-Aortic Balloon Pumo Counterpulsation? Randomized Study on Its Use in Chronic Heart Failure Progressing to Cardiogenic Shock

Cardiogenic shock (CS) remains a condition with extremely high mortality (around 50%). While most therapies for this pathology have been studied in CS secondary...